1
|
Zhang Z, Chi XY, Zhang GY, Zhang Z, Lu SH, Li MJ, Li LJ, Zhang JL, Shao FZ, Zhang Y, Hou LH, Chen W. A retrospective survey on the effectiveness of vaccines administered to individuals in China with regard to inactivated COVID-19 vaccines, Ad5-nCoV and/or aerosolized Ad5-nCoV. Emerg Microbes Infect 2024; 13:2396875. [PMID: 39178194 PMCID: PMC11370693 DOI: 10.1080/22221751.2024.2396875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2024] [Revised: 08/15/2024] [Accepted: 08/21/2024] [Indexed: 08/25/2024]
Abstract
We administered a questionnaire to participants who received different vaccination regimens to evaluate the effectiveness of Ad5-vectored COVID-19 vaccines. The results showed that administration of intramuscular Ad5-nCoV provided 21.32% more protection against SARS-CoV-2 infection than that of the inactivated COVID-19 vaccine in people who had received only one type of COVID-19 vaccine. Furthermore, aerosolized Ad5-nCoV exhibited good protection, whether it was administered as a homologous booster to people vaccinated with the intramuscular Ad5-nCoV or as a heterologous booster to people vaccinated with inactivated COVID-19 vaccines. Our research indicates that Ad5-nCoV is an effective booster. This finding supports the future selection of COVID-19 immunization strategies.
Collapse
Affiliation(s)
- Zhe Zhang
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| | - Xiang-Yang Chi
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| | - Guan-Ying Zhang
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| | - Zhang Zhang
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| | - Song-He Lu
- The Fourth Military Medical University, Xi'an, People’s Republic of China
| | - Meng-Jing Li
- The Eastern Theater Navy, Ningbo, People’s Republic of China
| | - Liang-Jun Li
- The Chinese People's Armed Police Force (PAP) Shanghai Corps, Shanghai, People’s Republic of China
| | - Jin-Long Zhang
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| | - Fang-Ze Shao
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| | - Yue Zhang
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| | - Li-Hua Hou
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| | - Wei Chen
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, People’s Republic of China
| |
Collapse
|
2
|
Su YW, Qiu YZ, Wang YH, Xu Y, Huang CC, Zhang Q, Su C, Ma JH, Liu W, Liu Y, Zhao MS, Yang HY, Li CL, Lu X. Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial. Vaccine 2024; 42:2438-2447. [PMID: 38461050 DOI: 10.1016/j.vaccine.2024.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 02/20/2024] [Accepted: 03/03/2024] [Indexed: 03/11/2024]
Abstract
Continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants urges the development of new vaccines. We assessed the safety and immunogenicity of SYS6006.32, a bivalent vaccine (XBB.1.5/BQ.1), in healthy adults who had received SARS-CoV-2 primary vaccination. In a randomised, double-blinded, active-controlled trial, 200 participants were randomised to receive one dose of SYS6006.32 (N = 100) or a prototype-based, monovalent control vaccine SYS6006 (N = 100). Adverse events (AEs) were collected through the study. Immunogenicity was assessed by live-virus neutralising antibody (Nab) and pseudovirus Nab. 61 (61.0 %) and 60 (60.0 %) participants reported AE in the SYS6006.32 and SYS6006 groups, respectively. Most AEs were grade 1 or 2. Pain and fever were the most common injection-site and systemic AEs, respectively. No serious AEs were observed. SYS6006.32 heterologous boosting induced robust Nab responses against BA.5, XBB.1.5 and EG.5 with live-virus Nab geometric mean titres (GMTs) increased by 17.1-, 34.0-, and 48.0-fold, and pseudovirus Nab GMTs increased by 12.2-, 32.0-, and 35.1-fold, respectively, 14 days after vaccination. SYS6006.32 demonstrated a superior immunogenicity to SYS6006. SYS6006.32 also induced robust pseudovirus Nab responses against XBB.1.16, XBB.2.3, and BA.2.86, with GMTs 3- to 6-fold higher than those induced by SYS6006. In conclusion, SYS6006.32 showed good safety profile and superior immunogenicity to the monovalent vaccine SYS6006.
Collapse
Affiliation(s)
- Yu-Wen Su
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China; National Vaccine Innovation Platform, School of Pharmacy, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China
| | - Yuan-Zheng Qiu
- CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang 050011, Hebei Province, China
| | - Yuan-Hui Wang
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China
| | - Yan Xu
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China
| | - Chao-Chao Huang
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China
| | - Qing Zhang
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China; National Vaccine Innovation Platform, School of Pharmacy, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China
| | - Chang Su
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China; National Vaccine Innovation Platform, School of Pharmacy, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China
| | - Jun-Heng Ma
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China; National Vaccine Innovation Platform, School of Pharmacy, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China
| | - Wen Liu
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China; National Vaccine Innovation Platform, School of Pharmacy, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China
| | - Yan Liu
- Institute for In Vitro Diagnostic Regents Control, National Institutes for Food and Drug Control, Beijing 100050, China
| | - Mao-Sheng Zhao
- CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang 050011, Hebei Province, China
| | - Han-Yu Yang
- CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang 050011, Hebei Province, China
| | - Chun-Lei Li
- CSPC Megalith Biopharmaceutical Co. Ltd, Shijiazhuang 050011, Hebei Province, China.
| | - Xiang Lu
- National Vaccine Innovation Platform, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China; National Vaccine Innovation Platform, School of Pharmacy, Nanjing Medical University, Nanjing 211166, Jiangsu Province, China.
| |
Collapse
|